Skip to main content

Animations

MJFF Publications

7641 - 7650 of 8808 Results
Title
Year
  • Year
  • 2020
  • 2017
  • 2015
  • 2020
  • 2013
  • 2014
  • 2022
  • 2018
  • 2020
  • 2014
  • Summary Details
    OPEN
    Title: A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson's disease
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.10.029
    Citation Count: 19
  • Summary Details
    OPEN
    Title: Impaired emotion processing in functional (psychogenic) tremor: A functional magnetic resonance imaging study
    Journal Name: NeuroImage: Clinical
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.nicl.2017.10.020
    Citation Count: 79
  • Summary Details
    OPEN
    Title: Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(15)00178-7
    Citation Count: 207
  • Summary Details
    OPEN
    Title: Fox Insight collects online, longitudinal patient-reported outcomes and genetic data on Parkinson’s disease
    Journal Name: Scientific Data
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41597-020-0401-2
    Citation Count: 98
  • Summary Details
    OPEN
    Title: Loss of Leucine-Rich Repeat Kinase 2 (LRRK2) in Rats Leads to Progressive Abnormal Phenotypes in Peripheral Organs
    Journal Name: PLoS ONE
    Publisher: Public Library of Science (PLoS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc0
    DOI - Digital Object Identifier: 10.1371/journal.pone.0080705
    Citation Count: 180
  • Summary Details
    OPEN
    Title: The hTH-GFP Reporter Rat Model for the Study of Parkinson's Disease
    Journal Name: PLoS ONE
    Publisher: Public Library of Science (PLoS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1371/journal.pone.0113151
    Citation Count: 20
  • Summary Details
    OPEN
    Title: Melanocortin 1 receptor activation protects against alpha-synuclein pathologies in models of Parkinson’s disease
    Journal Name: Molecular Neurodegeneration
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1186/s13024-022-00520-4
    Citation Count: 15
  • Summary Details
    OPEN
    Title: The glycoprotein GPNMB attenuates astrocyte inflammatory responses through the CD44 receptor
    Journal Name: Journal of Neuroinflammation
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1186/s12974-018-1100-1
    Citation Count: 148
  • Summary Details
    OPEN
    Title: Human plasma biomarker responses to inhalational general anaesthesia without surgery
    Journal Name: British Journal of Anaesthesia
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.bja.2020.04.085
    Citation Count: 40
  • Summary Details
    OPEN
    Title: Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinson's disease subjects
    Journal Name: Neuroscience Letters
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.neulet.2014.04.027
    Citation Count: 130
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.